STOCK TITAN

West Pharmaceutical Services, Inc. - WST STOCK NEWS

Welcome to our dedicated page for West Pharmaceutical Services news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharmaceutical Services stock.

West Pharmaceutical Services, Inc. (NYSE: WST) is a global leader in the design and manufacturing of innovative solutions for injectable drug administration systems. Headquartered in Exton, Pennsylvania, West collaborates closely with healthcare partners from concept to patient delivery, ensuring efficiency, reliability, and safety in packaging and delivery systems. The company operates through two main segments: Proprietary Products and Contract-Manufactured Products. Proprietary Products, contributing approximately 80% of total revenue, include elastomer-based packaging components such as stoppers, seals, and plungers, as well as non-glass containment solutions and auto-injectors for injectable drugs. The Contract-Manufactured Products segment, accounting for the remaining 20%, focuses on manufacturing components for drug-injection devices and healthcare diagnostic devices.

West's commitment to cutting-edge technology, quality systems, and global regulatory compliance has positioned it as a key supplier to the pharmaceutical, biotechnology, and generic drug industries. The company supports its customers through sales, manufacturing, and research and development locations across North and South America, Europe, Asia, and Australia.

In recent financial results, West reported a solid performance despite the expected decline in COVID-19 related sales. The second-quarter and third-quarter 2023 showed a decline in net sales for Proprietary Products primarily due to reduced pandemic-related demand. However, the Contract-Manufactured Products segment demonstrated strong growth, with net sales increasing significantly. For the full-year 2023, West experienced challenges with headwinds from lower pandemic-related sales but saw gains in high-value product components and devices, as well as contract manufacturing.

West continues to innovate, recently expanding its administration systems portfolio with the FDA-cleared Vial2Bag Advanced® 13mm admixture device, enhancing drug preparation and delivery options at the point-of-care. As the company celebrates its 100-year milestone, it remains focused on meeting customer demand and investing in high-value products and manufacturing capacity to fuel future growth.

For more detailed information about West's latest financial performance and strategic initiatives, visit the company's official website.

Rhea-AI Summary

West Pharmaceutical Services (NYSE: WST) will release its second-quarter 2024 financial results on July 25, 2024, before the market opens. A conference call is scheduled for the same day at 9:00 a.m. Eastern Time to discuss the results and business outlook. Interested participants must register in advance to receive the dial-in number and unique PIN for the call. The call will be accompanied by a slide presentation available on the company's website. A live audio webcast and subsequent replay will also be accessible in the 'Investors' section of the website, with the replay available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
conferences
-
Rhea-AI Summary

West Pharmaceutical Services (NYSE: WST) has introduced Daikyo Crystal Zenith® (CZ) Nested Vials at the International Society for Cell and Gene Therapy Annual Meeting in Vancouver, Canada from May 29-June 1, 2024.

Designed to meet ISO 8362-1 standards, the vials are compatible with a range of aseptic fill-finish equipment. They offer features such as break resistance, low particulate specification, and low risk of chemical interaction.

Available in 2mL and 10mL sizes, the vials come with flexible closure options and are suitable for storing gene therapy drugs from preclinical to commercial phases. Chief Commercial Officer Cindy Reiss-Clark stated that this product expands CZ's platform for flexible filling solutions of sensitive molecules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
Rhea-AI Summary

West Pharmaceutical Services (NYSE: WST) announced its participation in the William Blair 44th Annual Growth Stock Conference in Chicago, IL, on June 4, 2024, at 8:00 AM CT. The event will feature a live audio webcast available on the company's website, www.westpharma.com, in the 'Investors' section. The webcast replay will be accessible for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences
Rhea-AI Summary

West Pharmaceutical Services, Inc. (NYSE: WST) will participate in the Bank of America Securities Healthcare Conference in Las Vegas, NV on May 14, 2024. The company will present at 11:20 AM PT and offer a live audio webcast on their website. Investors can access the webcast on www.westpharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
conferences
-
Rhea-AI Summary
West Pharmaceutical Services, Inc. (WST) announced its first-quarter 2024 results, showing a decline in net sales by 3.0% and a decrease in reported-diluted EPS by 16.2%. However, adjusted-diluted EPS declined by 21.2%. The Company reaffirmed its full-year 2024 net sales guidance and raised the adjusted-diluted EPS guidance range. Additionally, a third-quarter 2024 dividend of $0.20 per share was declared. The Company is actively managing costs and making strategic investments for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
dividends earnings
-
Rhea-AI Summary
West Pharmaceutical Services, Inc. (WST) will release its first-quarter financial results on April 25, 2024, followed by a conference call to discuss business expectations. Participants can register in advance to ask questions to Management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary
West Pharmaceutical Services, Inc. (WST) will present at two upcoming healthcare conferences in March 2024, providing opportunities for investors to learn about the company's latest developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences
-
Rhea-AI Summary
West Pharmaceutical Services, Inc. declares a dividend of $0.20 per share for the second quarter of 2024, payable on May 1, 2024, to shareholders of record as of April 24, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
dividends
-
Rhea-AI Summary
West Pharmaceutical Services, Inc. (WST) reported strong financial results for Q4 and full-year 2023, with net sales growth and EPS increases. The company introduced 2024 financial guidance with expected organic sales growth and adjusted EPS range. The Proprietary Products segment saw growth in HVP components and devices, while the Contract-Manufactured Products segment showed growth in medical device and diagnostic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.08%
Tags
Rhea-AI Summary
West Pharmaceutical Services, Inc. (WST) has been recognized as one of America's Greatest Workplaces for Diversity 2024 by Newsweek and Plant-A Insights Group. The company's commitment to diversity, equity, and inclusion is evident through its global impact and long-standing dedication. West's emphasis on diversity is reflected in its recruitment strategy, with 44% of senior leaders being women and/or people of color, and 53% of them being promoted to senior leadership in 2023. Additionally, West supports underserved communities through donations of over $1 million annually to over 40 charities. This recognition highlights West's efforts in fostering a diverse and inclusive work environment, which is crucial for attracting top talent and business partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none

FAQ

What does West Pharmaceutical Services, Inc. specialize in?

West Pharmaceutical Services specializes in designing and manufacturing innovative injectable drug administration systems and packaging solutions for the pharmaceutical, biotechnology, and generic drug industries.

Where is West Pharmaceutical Services headquartered?

West Pharmaceutical Services is headquartered in Exton, Pennsylvania, U.S.

What are the two main segments of West Pharmaceutical Services?

The two main segments are Proprietary Products, which include elastomer-based packaging and delivery components, and Contract-Manufactured Products, which focus on drug-injection and diagnostic device components.

How much of West's revenue comes from international markets?

Approximately 55% of West's revenue is generated from international markets, with 45% coming from the United States.

What recent products has West Pharmaceutical Services launched?

West recently launched the Vial2Bag Advanced® 13mm admixture device, a needle-free solution designed for immediate use IV drug transfer, complementing their existing 20mm device.

What are some of the key products offered by West Pharmaceutical Services?

Key products include elastomer-based packaging components like stoppers, seals, plungers, non-glass containment solutions, and auto-injectors for injectable drugs.

How did West Pharmaceutical Services perform in the latest financial quarters?

In recent quarters, West saw a decline in Proprietary Product sales due to reduced COVID-19 related demand but experienced significant growth in Contract-Manufactured Products. Overall, the company reported a strong base organic sales growth despite pandemic-related headwinds.

What are West Pharmaceutical Services' long-term growth strategies?

West focuses on investing in high-value product components and expanding contract manufacturing capacity to support customer demand and drive future organic sales growth.

How does West Pharmaceutical Services support its customers globally?

West supports customers from sales, manufacturing, and R&D locations across North and South America, Europe, Asia, and Australia, ensuring a comprehensive global presence.

Where can I find more information about West Pharmaceutical Services?

For more detailed information, visit West Pharmaceutical Services' official website at www.westpharma.com.

West Pharmaceutical Services, Inc.

NYSE:WST

WST Rankings

WST Stock Data

23.17B
72.84M
0.57%
96.06%
1.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
EXTON